利妥昔单抗在重症皮肤病中的应用进展

Rituximab Use in Severe Skin Diseases

免疫性疱病、结缔组织病、血管炎等疾病属于皮肤科中的重症、难治性皮肤病。近年来,多种生物制剂和靶向治疗陆续应用于上述疾病中。目前在美国与欧洲,利妥昔单抗已作为中重度寻常型天疱疮、ANCA相关性血管炎的一线治疗方案。本文将对利妥昔单抗治疗上述疾病的作用机制、治疗方案以及安全性等方面做一概述。

Autoimmune bullous diseases, connective tissue disease, vasculitis and other diseases belong to severe and refractory skin diseases in dermatology. In recent years, a variety of biological agents and targeted therapy have been used in the above diseases. Currently, in the United States and Europe, rituximab has been used as a first-line treatment for moderate to severe pemphigus vulgaris and ANCA-associated vasculitis. This article will give an overview of the mechanism of action, treatment options and safety of rituximab in the treatment of the above diseases.